Compare · COSM vs PETQ
COSM vs PETQ
Side-by-side comparison of Cosmos Health Inc. (COSM) and PetIQ Inc. (PETQ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COSM and PETQ operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- PETQ is the larger of the two at $570.2M, about 26.5x COSM ($21.5M).
- COSM has hit the wire 4 times in the past 4 weeks while PETQ has been quiet.
- PETQ has more recent analyst coverage (8 ratings vs 0 for COSM).
- Company
- Cosmos Health Inc.
- PetIQ Inc.
- Price
- $0.22+3.81%
- $30.99+0.02%
- Market cap
- $21.5M
- $570.2M
- 1M return
- +11.60%
- -
- 1Y return
- -98.70%
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 4
- 0
- Recent ratings
- 0
- 8
Cosmos Health Inc.
Cosmos Holdings Inc. operates as a vertically integrated pharmaceutical company. It offers proprietary line of branded and generic pharmaceuticals, nutraceuticals, over-the-counter (OTC) medications, health care, baby products, medical devices, and other products through its distribution channels and e-commerce market place. The company identifies, acquires, develops, and commercializes products that enhance patients' lives and outcomes, as well as has distribution centers in Greece, and the United Kingdom; and warehousing facility. It serves wholesale pharmaceutical distributors and independent retail pharmacies. The company was formerly known as Prime Estates and Developments, Inc. and changed its name to Cosmos Holdings Inc. in November 2013. Cosmos Holdings Inc. was incorporated in 2009 and is based in Chicago, Illinois.
PetIQ Inc.
PetIQ, Inc. operates as a pet medication and wellness company. It operates in two segments, Products and Services. The company offers Rx pet medications, which include heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and co-develops and manufactures its own proprietary value-branded products, as well as distributes third-party branded medications. It also provides OTC medications and supplies primarily within the flea and tick control, and behavior management categories of the health and wellness industry in various forms, such as spot on (topical) treatments, chewables, oral tablets, and collars. In addition, the company offers health and wellness products that include dental treats and nutritional supplements, which comprise hip and joint, vitamins, and skin and coat products. The company provides its products primarily under the PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, PetLock, Heart Shield Plus, TruProfen, Betsy Farms, PetAction, Minties, Vera, and Delightibles brands. In addition, the company offers a suite of services at community clinics and wellness centers hosted at pet retailers across 41 states, including diagnostic tests, vaccinations, prescription medications, microchipping, and wellness checks. It operates through approximately 60,000 points of distribution across veterinarian, retail, and e-commerce channels. The company was founded in 2010 and is headquartered in Eagle, Idaho.
Latest COSM
- Cosmos Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway
- SEC Form 10-Q filed by Cosmos Health Inc.
- SEC Form NT 10-Q filed by Cosmos Health Inc.
- Chief Executive Officer Siokas Grigorios bought $70,000 worth of shares (349,825 units at $0.20), increasing direct ownership by 2% to 14,597,917 units (SEC Form 4)
- Chief Financial Officer Terzis Georgios was granted 328,407 shares, increasing direct ownership by 15% to 2,563,805 units (SEC Form 4)
- Chief Executive Officer Siokas Grigorios bought $140,000 worth of shares (766,284 units at $0.18), increasing direct ownership by 6% to 14,248,092 units (SEC Form 4)
- Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels
- SEC Form RW filed by Cosmos Health Inc.
- Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units
Latest PETQ
- PetIQ Names Camillo Pane as Chief Executive Officer
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- SEC Form 15-12G filed by PetIQ Inc.
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- Amendment: SEC Form SC 13G/A filed by PetIQ Inc.
- Chief Financial Officer Glasman Zvi returned 25,800 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Huff Scott returned 6,077 shares to the company, closing all direct ownership in the company (SEC Form 4)
- EVP Manufacturing & Sup. Chain Lyon Chad D. returned 10,659 shares to the company, closing all direct ownership in the company (SEC Form 4)
- EVP, GENERAL COUNSEL Carter William J. returned 3,497 shares to the company, closing all direct ownership in the company (SEC Form 4)